Phase 1a/1b single and multiple ascending dose study of oral CDX-7108 in healthy adult
subjects and a single dose proof-of-concept study of oral CDX-7108 in subjects with exocrine
pancreatic insufficiency.
No clinical studies have yet been performed with CDX-7108 and its effects in humans are
unknown. This is the first-in-human (FIH) study of CDX-7108, which aims to assess the safety,
tolerability, pharmacokinetics (PK) of escalating single and multiple oral doses of CDX-7108
in healthy adult subjects and to evaluate the pharmacodynamics of a single dose of oral
CDX-7108 in a proof-of-concept (POC) study in subjects with exocrine pancreatic insufficiency
(EPI).